HC Wainwright restated their buy rating on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a research report report published on Thursday morning, Marketbeat.com reports. They currently have a $52.00 target price on the stock.

Other equities analysts have also issued research reports about the stock. BMO Capital Markets cut their price target on shares of Pacira Pharmaceuticals from $42.00 to $40.00 and set a market perform rating on the stock in a report on Thursday, August 3rd. Canaccord Genuity reiterated a buy rating and set a $56.00 price target on shares of Pacira Pharmaceuticals in a report on Monday, July 31st. ValuEngine lowered shares of Pacira Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 4th. Jefferies Group LLC cut their price target on shares of Pacira Pharmaceuticals to $52.00 and set a buy rating on the stock in a report on Thursday. Finally, Janney Montgomery Scott upgraded shares of Pacira Pharmaceuticals from a sell rating to a neutral rating and set a $31.00 price target on the stock in a report on Monday, August 21st. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. Pacira Pharmaceuticals currently has an average rating of Hold and a consensus target price of $49.71.

Pacira Pharmaceuticals (NASDAQ PCRX) traded up $1.90 during midday trading on Thursday, hitting $42.05. 787,300 shares of the company’s stock were exchanged, compared to its average volume of 927,270. Pacira Pharmaceuticals has a 12-month low of $29.81 and a 12-month high of $58.95. The company has a current ratio of 6.99, a quick ratio of 7.26 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. The company had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. Pacira Pharmaceuticals’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 earnings per share. sell-side analysts predict that Pacira Pharmaceuticals will post -0.96 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “HC Wainwright Reaffirms “Buy” Rating for Pacira Pharmaceuticals, Inc. (PCRX)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-pacira-pharmaceuticals-inc-pcrx/1698615.html.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total value of $127,191.75. Following the completion of the sale, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at $783,216. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total transaction of $37,740.60. Following the completion of the sale, the director now directly owns 3,518 shares of the company’s stock, valued at $127,175.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,390 shares of company stock valued at $1,215,480. Insiders own 6.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of PCRX. Principal Financial Group Inc. bought a new stake in Pacira Pharmaceuticals in the first quarter valued at $237,000. Teachers Advisors LLC increased its stake in Pacira Pharmaceuticals by 238.5% in the first quarter. Teachers Advisors LLC now owns 212,792 shares of the company’s stock valued at $9,703,000 after purchasing an additional 149,938 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Pacira Pharmaceuticals by 25.8% in the first quarter. TIAA CREF Investment Management LLC now owns 136,167 shares of the company’s stock valued at $6,209,000 after purchasing an additional 27,942 shares in the last quarter. Vanguard Group Inc. increased its stake in Pacira Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 2,860,092 shares of the company’s stock valued at $130,420,000 after purchasing an additional 112,853 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Pacira Pharmaceuticals by 5.3% in the first quarter. Geode Capital Management LLC now owns 367,089 shares of the company’s stock valued at $16,739,000 after purchasing an additional 18,559 shares in the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.